TAMPA, Fla. — The Food and Drug Administration has granted accelerated approval to the experimental drug lecanemab, shown to slow down the progression of Alzheimer’s disease in its early stages. Eisai ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback